Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients
Phase 4
- Conditions
- Diabetic Retinopathy
- Interventions
- Registration Number
- NCT04140201
- Lead Sponsor
- Alaa Hassan ElBaz
- Brief Summary
The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients
- Detailed Description
The investigator study compare the effect of lipid lowering agent on the enhancement of visual acuity and on reduction of macular edema in patients with diabetic retinopathy and also compare their effect on reduction of cardiovascular risk on diabetic patients via assessment of ASCVD risk score
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- type 2diabetes
- Non proliferative diabetic retinopathy
Exclusion Criteria
- Uncontrolled glycemic level
- proliferative diabetic retinopathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Receive oral hypoglycemic +fibrate Fenofibrate 200mg Fenofibrate +standard treatment Receive oral hypoglycemic +statin Simvastatin 40mg Simvastatin + standard treatment Receive oral hypoglycemic +omega 3 Omega 3 fatty acid Eicosapentanoic acid + standard treatment
- Primary Outcome Measures
Name Time Method The 80 participants will be evaluated through reduction of macular edema 18 weeks assessed by ocular coherence tomography
- Secondary Outcome Measures
Name Time Method The 80 participants will be evaluated through reduction of cardiovascular risk 18 weeks assessed by ASCVD risk score